ArticleAnnals of surgical oncology2026
Treatment for Oligo-recurrence of Diffuse Pleural Mesothelioma After Extended Pleurectomy/Decortication.
Article in Annals of surgical oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundWe evaluate recurrence patterns and assess the efficacy of local treatment for oligo-recurrence in patients with diffuse pleural mesothelioma (PM) following extended pleurectomy/decortication (P/D) with multimodal therapy.
methodsThis retrospective study included 69 patients with PM treated at the Institute of Science Tokyo Hospital from October 2010 to September 2025. All the patients underwent extended P/D and intraoperative hyperthermic cisplatin perfusion. Oligo-recurrence was defined as a small number of recurrences that would be treated with local treatment. Recurrence patterns, treatments, and survival outcomes were examined.
resultsMacroscopic complete resection was achieved in all patients, and there was one in-hospital mortality (1.4%). Sixty-one patients (88.4%) received multimodal therapy. Recurrence occurred in 52 patients (75%). The median recurrence-free survival (RFS) was 15.0 months. The type of recurrence was local in 32 (62%) patients, distant in six (12%), and both in 14 (27%). Local treatment (second surgery 14; radiation therapy 2) was administered to 16 patients with oligo-recurrence. Chest wall excision was the most common surgical procedure. Seven patients underwent repeated local treatments (surgery 20; radiation therapy 7). The median post-recurrence survival (PRS) of 52 patients was 13.9 months. The PRS with systemic chemotherapy was 11.4 months, while the PRS with the addition of oligo-recurrence treatment was 45.6 months. Multivariate analysis revealed that disease-free interval and oligo-recurrence were significantly favorable factors for PRS.
conclusionsLocal treatment, a second surgery and radiation therapy, for oligo-recurrence of PM after extended P/D showed a favorable survival outcome. Tailored treatment for recurrent PM is warranted.
Indexed as
Identifiers
42472754What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.